- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Hubbard Today
By the People, for the People
Texas Leads Ibogaine Research to Treat Opioid Addiction
New executive order and state funding aim to unlock psychedelic's potential while addressing safety concerns
Apr. 19, 2026 at 4:43pm
Got story updates? Submit your updates here. ›
New research initiatives aim to unlock the therapeutic potential of the psychedelic ibogaine while mitigating its dangerous cardiac side effects.Hubbard TodayThe U.S. government has taken major steps to support research into ibogaine, a psychedelic compound that has shown promise in treating opioid addiction. President Trump signed an executive order fast-tracking psychedelics for mental health treatment, while Texas allocated $50 million in state funding for clinical trials on ibogaine's potential to treat opioid use disorder, PTSD, depression, and traumatic brain injury. However, safety concerns around ibogaine's cardiac risks remain a significant challenge.
Why it matters
The opioid epidemic continues to devastate communities across the U.S., and new treatment options are desperately needed. Ibogaine has demonstrated the ability to rapidly reduce opioid withdrawal symptoms and cravings, but its use has been limited due to safety risks. The new government initiatives aim to rigorously study ibogaine's benefits and develop safer formulations that could expand access to this potentially life-saving treatment.
The details
Ibogaine is a psychoactive compound found in the root bark of the Tabernanthe iboga plant, native to Central and West Africa. It has been used for generations in Bwiti spiritual ceremonies and more recently gained attention for its apparent ability to curb opioid and cocaine addiction. However, ibogaine also carries significant cardiac risks, including fatal arrhythmias, that have limited its use, especially in unregulated settings.
- On April 18, 2026, President Trump signed an executive order fast-tracking research into psychedelics like ibogaine for mental health treatment.
- In June 2025, Texas Governor Greg Abbott signed a bill allocating up to $50 million in state funding for clinical trials on ibogaine's potential to treat opioid use disorder, PTSD, depression, and traumatic brain injury.
The players
Greg Abbott
The Governor of Texas who signed a bill supporting ibogaine research in the state.
Bryan Hubbard
The CEO of Americans for Ibogaine, a leading advocate for legislation supporting ibogaine as a treatment option.
What’s next
Researchers are currently working on developing safer ibogaine-inspired medicines that may retain the anti-addiction effects with less impact on the heart. The results of the clinical trials funded by Texas and the federal government will be crucial in determining if ibogaine or its analogs can be safely incorporated into mainstream addiction treatment.
The takeaway
The opioid crisis demands bold thinking, and ibogaine represents a promising but high-risk potential solution. While the safety concerns around ibogaine are significant, the new government initiatives to study it rigorously could unlock its therapeutic potential and lead to the development of safer alternatives that could expand access to this novel treatment approach.
